Status
Conditions
Treatments
About
The goal of HeadSMART II (HEAD injury Serum markers and Multi-modalities for Assessing Response to Trauma II) is to develop an In-Vitro Diagnostic, the BRAINBox TBI test, to aid in the diagnosis and prognosis of patients with mild traumatic brain injury, by incorporating blood biomarkers, clinical assessments, and tools to measure associated neurocognitive impairments.
Full description
This study proposes to collect data using a multi-modality approach including blood biomarkers, clinical assessments, neurocognitive performance, and neuropsychological characteristics, to identify subjects with a mild Traumatic Brain Injury (TBI) and their likelihood of chronic symptoms.
This is an observational study with an expectation of enrolling up to 2000 subjects. These subjects will include the intended use population, subjects presenting to the Emergency Department or Urgent Care with a blunt head trauma. Data will be collected across four time points, T=0, 14 days, 30 days and 90 days, to allow for building and validating the algorithms for both diagnosis and prognosis claims.
Control populations, healthy and trauma only (no head trauma) will be included for assay development. Data will be collected for these groups at T=0 and 14 days (trauma control only).
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Target Condition Subjects
Inclusion Criteria:
Exclusion Criteria:
Control Subjects
Inclusion:
Exclusion:
2,000 participants in 3 patient groups
Loading...
Central trial contact
Donna Edmonds; Andrea Brown, MS
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal